| Literature DB >> 31174274 |
Nurudeen Olalekan Oloso1, Ismail Adewuyi Adeyemo2, Henriette van Heerden3, Olubunmi Gabriel Fasanmi4,5, Folorunso Oludayo Fasina6,7.
Abstract
Salmonella is among the pathogens on the high global priority lists for monitoring for studies on the discovery of new antimicrobials and understanding of how antimicrobial resistance (AMR) develops. AMR in connection with antibiotic usage patterns has been considered as a strong factor and contributor to the AMR pool. The purposes of use, pattern of antimicrobial drug administration, as well as the prevalence of AMR in Salmonella originating from the Nigeria broiler production value chain (NBPVC) was explored. A well-structured questionnaire on antimicrobial usage (n = 181) was used for sampling that focused on 21 antimicrobials from 151 locations. Simultaneously, AMR testing for 18 commonly used antimicrobials on Salmonella in humans was also carried out. Antimicrobial resistance Salmonella spp. were isolated in 23% of the samples (261 of 1135 samples from the broiler input, products, and the environment) using modified ISO 6579 and invA PCR protocols. Over 80% of the antimicrobials used in the NBPVC were administered without a veterinarian prescription. Prevalence of antimicrobial administration without prescription were as follows: live-bird-market (100%), hatchery (86.7%), grow-out-farm (75%), and breeder (66.7%). Widespread prophylactic and metaphylactic use of antimicrobials were recorded with the highest use seen for enrofloxacin (63% and 24%), tetracycline (58% and 33%), and erythromycin (50% and 17%). Antimicrobial resistance was highest for flumequine (100%), penicillin (95%), and perfloxacin (89%). High levels of use without laboratory support of a newer generation of a class of antibiotics suspected to confer high resistance on older generations of the same class (quinolones) was observed.Entities:
Keywords: antimicrobial stewardship; antimicrobial usage; breeder broiler; environment; food animal residue; hatchery; live bird market
Year: 2019 PMID: 31174274 PMCID: PMC6627717 DOI: 10.3390/antibiotics8020075
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Schematic diagram of the study of antimicrobial susceptibility testing of Salmonella isolates and antimicrobial drug administration in the broiler production value chain in Nigeria (NBPVC).
Demography of antimicrobial resistance profiling of Salmonella spp. at the production stages along the broiler value chain in Nigeria.
| ProductionStages | Location Sampled for AU (n) | AU Samples per Location (n) | AU Responses per Stage (n) | AU Without Lab Test (n (%) | Samples per Stage for | ||||
|---|---|---|---|---|---|---|---|---|---|
| Based on Locations | Based on Samples | ||||||||
| Breeder | 45 | 1 | 45 | 30 (66.7%) | 16 | 332 | 56.25% | 22.29% | 146 |
| Hatchery | 15 | 1 | 15 | 13 (86.7%) | 7 | 144 | 57.13% | 32.64% | 102 |
| Grow-out | 76 | 1 | 76 | 57 (75.0%) | 22 | 373 | 54.55% | 18.77% | 111 |
| Abattoir | ND | ND | ND | ND | 6 | 151 | 33.33% | 12.58% | 46 |
| LBM | 15 | 3 | 45 | 45 (100%) | 5 | 79 | 100% | 49.37% | 65 |
| Retail | ND | ND | ND | ND | 4 | 56 | 25.00% | 21.43% | 37 |
| Total | 151 | NA | 181 | 145(80.1%) | 60 | 1135 | 55.00% | 23.00% | 507 |
Note: AU = Antimicrobial usage; NA = Not applicable; ND = Not done; lab. = laboratory; Stage = production stage; Salm. = Salmonella; n = number; Salm. prevalence rates based on locations = Percentage of number of location that had at least one of the samples from the location positive for Salmonella detection; Salm. prevalence rate based on samples = Percentage of number of Salmonella positive samples from the total sample collected per stage. Salmonella positivity was based on both biochemical tests and invA gene PCR detection. LBM = Live Bird Market.
Antibiotic usage and antimicrobial susceptibility testing of Salmonella isolates along the broiler production chain of Nigeria.
| Antibiotic | Class (Generation) | Antibiotic Usage Responses | Antimicrobial Susceptibility Testing Report | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prophylactic (%) | Therapeutic Without Test (%) | Total usage Without Test % | Categorization of Usage Without Test | Antim. Conc. (µg) | Resistance (%) | Intermediate (%) | Total AMR % | AMR Categorization | ||
| AMC | β –Lactam (4th) | 26.5 | 42.5 | 69 | H | 30 | 65.2 | 15.5 | 80.7 | VH |
| AMP | β –Lactam (3th) | 40.3 | 20.4 | 60.7 | H | 10 | 88.5 | 3.2 | 91.7 | VH |
| CRO | β –Lactam (3th) | 1.7 | 12.2 | 13.9 | VL | 30 | 33.2 | 12.3 | 45.5 | L |
| CIP | Quinolone (2th) | 35.4 | 33.7 | 69.1 | H | 5 | 64.2 | 30.2 | 94.4 | VH |
| CT | Polypeptide (1st) | 31.9 | 22 | 53.9 | H | 10 | 59.4 | 0 | 59.4 | H |
| DO | Tetracycline (NGC) | 42 | 28.2 | 70.2 | H | 30 | 54.9 | 16.3 | 71.2 | H |
| ENR | Quinolone (2th) | 63 | 24.3 | 87.3 | VH | 5 | 81.0 | 19.0 | 100 | VH |
| E | Macrolide (NGC) | 50.8 | 17.7 | 68.5 | H | 15 | 87.2 | 11.0 | 98.2 | VH |
| FFC | Phenicol (NGC) | 2.2 | 16.6 | 18.8 | VL | 30 | 27.7 | 14.0 | 41.7 | L |
| UB | Quinolone (1st) | 3.9 | 19.9 | 23.8 | VL | 30 | 100 | 0 | 100 | VH |
| CN | Aminoglycoside (NGC) | 25.4 | 43.6 | 69 | H | 120 | 8.4 | 1.6 | 10 | VL |
| N | Aminoglycoside (NGC) | 34.6 | 29.7 | 64.3 | H | 30 | 58.3 | 19.7 | 78 | VH |
| NOR | Quinolone (2th) | 8.3 | 39.2 | 47.5 | L | 10 | 33.1 | 19.7 | 52.8 | H |
| P | β –Lactam (1st) | 45.9 | 27.1 | 73 | H | 10 | 95.4 | 2.6 | 98 | VH |
| PEF | Quinolone (2th) | 13.3 | 29.3 | 42.6 | L | 5 | 89.6 | 0 | 89.6 | VH |
| S | Aminoglycoside (NGC) | 22.7 | 24.3 | 47 | L | 300 | 2.8 | 1.2 | 4 | VL |
| SXT | Sulfonamides (NGC) | 41.4 | 22.1 | 63.5 | H | 25 | 70.1 | 6.8 | 76.9 | VH |
| TE | Tetracycline (NGC) | 58.6 | 18.2 | 76.8 | VH | 30 | 74.6 | 6.2 | 80.8 | VH |
| TYL | Macrolides (NGC) | 11.1 | 43.6 | 54.7 | H | ND | ND | ND | ND | ND |
| TIA | Pleuromutilins (NGC) | 5.5 | 27.1 | 32.6 | L | ND | ND | ND | ND | ND |
| FUR | Nitrofuran (NGC) | 50.3 | 21 | 71.3 | H | ND | ND | ND | ND | ND |
AMC = Amoxicillin clavulanic, AMP = Ampicillin, CIP = Ciprofloxacin, CN = Gentamycin, CRO = Ceftriaxone, CT = Colistin, DO = Doxycycline, E = Erythromycin, ENR = Enrofloxacin, FFC = Florfenicol, FUR = Furazolidone, N = Neomycin 30, NOR = Norfloxacin, P = Penicillin G, PEF = Perfloxacin, S = Streptomycin, SXT = Co-trimoxazole (Trimethoprim-Sulphamethoxazole), TE = Tetracycline, TIA = Tiamulin, TYL = Tylosine, UB = Flumequine, n = number of sample or response for antibiotic usage and number of Salmonella isolates for antimicrobial susceptibility testing; % = Percentage of the observed over total for each antibiotics. ND = Not Done. NGC = No generation classification is applicable. VH = Very High, H = High, L = Low, VL = Very Low. Total Usage without test = Prophylactic + Therapeutic without test. Total antimicrobial resistance (AMR) = Resistance + Intermediate. Usage and AMR categorization = Categorization of total usage without test or total AMR into: No (≤1%), Very low (>1, ≤25%), Low (26 ≤ 50%), High (51 ≤ 75%), and Very high (≥75%). Antib conc. = Antibiotic concentration used for antimicrobial resistance testing. µg = microgram.
Figure 2Profiling of purposes of antimicrobial drug administration in the Nigeria broiler production chain Note: AMC = Amoxicillin clavulanic, AMP = Ampicillin, CIP = Ciprofloxacin, CN = Gentamycin, CRO = Ceftriaxone, CT = Colistin, DO = Doxycycline, E = Erythromycin, ENR = Enrofloxacin, FFC = Florfenicol, FUR = Furazolidone, N = Neomycin 30, NOR = Norfloxacin, P = Penicillin G, PEF = Perfloxacin, S = Streptomycin, SXT = Co-trimoxazole (Trimethoprim-Sulphamethoxazole), TE = Tetracycline, TIA = Tiamulin, TYL = Tylosine, UB = Flumequine.
Figure 3Resistance profile of 507 Salmonella isolates from the Nigeria broiler production value chain. (a) Distribution of resistance of 507 Salmonella isolates from the Nigeria broiler production value chain to each antibiotic; (b) Resistance profile of 507 Salmonella isolates from the Nigeria broiler production value chain to each antimicrobial. Note: AMC = Amoxicillin clavulanic 30 µg, AMP = Ampicillin 10 µg, CIP = Ciprofloxacin = 5 µg, CN = Gentamycin 120 µg, CRO = Ceftriaxone 30 µg, CT = Colistin 10 µg, DO = Doxycycline 30 µg, E = Erythromycin 15 µg, ENR = Enrofloxacin 5 µg, FFC = Florfenicol 30 µg, N = Neomycin 30 µg, NOR = Norfloxacin 10 µg, P = Penicillin G 10 µg, PEF = Perfloxacin 5µg, S = Streptomycin 300 µg, SXT = Co-trimoxazole (Trimethoprim-Sulphamethoxazole) 25 µg, TE = Tetracycline 30 µg, UB = Flumequine 30 µg.